33564-30-6 Usage
Uses
Used in Pharmaceutical Industry:
Cefoxitin sodium is used as a semi-synthetic antibiotic for treating various bacterial infections. Its application is due to its effectiveness against a broad spectrum of gram-negative and gram-positive bacteria, including anaerobes, and its resistance to β-lactamase inactivation.
Used in Clinical Settings:
Cefoxitin sodium is used as an antibiotic to combat bacterial infections in various clinical settings. Its application is based on its ability to interfere with bacterial cell wall synthesis, making it a valuable tool in treating a wide range of bacterial infections.
Brand Name:
In the United States, Cefoxitin sodium is marketed under the brand name Mefoxin, which is manufactured by Merck.
Originator
Mefoxin,Merck Sharp and Dohme,US,1978
Manufacturing Process
Benzhydryl 3-carbamoyloxymethyl-7α-hydroxy-7β-(2-thienylacetamido)
decephalosporanate, 543 mg, is stirred in 15 ml dry DMSO. Sodium hydride,
24 mg (48 mg of a 50% suspension of NaH in mineral oi1, which has been
washed with hexane to remove the oil), is added. When hydrogen evolution
has ceased, 126 mg dimethyl sulfate is added. The solution is stirred for one
hour at room temperature, diluted with 100 ml benzene and washed six times
with water; the last wash is made to pH 8, if necessary, by adding sodium
bicarbonate. The solution is dried over MgSO4, filtered and evaporated,
leaving benzhydryl 3-carbamoyloxymethyl-7β-(2-thienylacetamido)-7α-
methoxydecephalosporanate, which may be purified if desired by
chromatography on silica gel, eluting with 25:1 chloroformethyl acetate.Other methylating agents may be used in place of methyl sulfate, e.g., an
equimolar amount of methyl iodide, bromide or chloride, using the same
conditions, or methyl trifluoromethylsulfonate or trimethyloxonium
trinitrobenzenesulfonate. The solvent in the latter two reagents is dimethyl
ether-HMPA 1:1, using a reaction temperature of -20°C warming later to
25°C. In each instance, the benzhydryl 3-carbamoyloxymethyl-7β-(2-
thienylacetamido)-7α-methoxydecephalosporanate is obtained.Benzhydryl 3-carbamoyloxymethyl-7β-(2-thienylacetamido)-7α-
methoxydecephalosporanate (300 mg) in 0.5 ml in anisole and 2.5 ml of
trifluoroacetic acid is reacted for 15 minutes at 10°C. The resulting mixture is evaporated at reduced pressure and flushed twice with anisole. The residue is
dissolved in methylene chloride and extracted with 5% sodium bicarbonate
solution. The aqueous solution is adjusted to pH 1.8 with 5% phosphoric acid
and extracted with ethyl acetate. The organic solution is dried and evaporated
to yield the pure 3-carbamoyloxymethyl-7α-methoxy-7β-(2-
thienylacetamido)decephalosporanic acid, MP 165°C to 167°C. This may then
be converted to the sodium salt.
Therapeutic Function
Antibiotic
Clinical Use
Cefoxitin (Mefoxin) is a semisynthetic derivative obtainedby modification of cephamycin C, a 7α-methoxy-substitutedcephalosporin isolated independently from variousStreptomyces by research groups in Japan and the UnitedStates. Although it is less potent than cephalothin againstGram-positive bacteria and cefamandole against most of theEnterobacteriaceae, cefoxitin is effective against certainstrains of Gram-negative bacilli (e.g., E. coli, K. pneumoniae,Providencia spp., S. marcescens, indole-positiveProteus spp., and Bacteroides spp.) that are resistant to thesecephalosporins. It is also effective against penicillin-resistantS. aureus and N. gonorrhoeae. The activity of cefoxitin and cephamycins, in general,against resistant bacterial strains is because of their resistanceto hydrolysis by β-lactamases conferred by the 7α-methoxylsubstituent. Cefoxitin is a potent competitive inhibitor ofmany β-lactamases. It is also a potent inducer of chromosomallymediated β-lactamases. The temptation to exploit the β-lactamase–inhibiting properties of cefoxitin by combining itwith β-lactamase–labile β-lactam antibiotics should be temperedby the possibility of antagonism. In fact, cefoxitin antagonizesthe action of cefamandole against E. cloacae andthat of carbenicillin against P. aeruginosa. Cefoxitin aloneis essentially ineffective against these organisms.The pharmacokinetic properties of cefoxitin resemblethose of cefamandole. Because its half-life is relativelyshort, cefoxitin must be administered 3 or 4 times daily.Solutions of the sodium salt intended for parenteral administrationare stable for 24 hours at room temperature and 1week if refrigerated. 7α-Methoxyl substitution stabilizes, tosome extent, the β-lactam to alkaline hydrolysis.The principal role of cefoxitin in therapy seems to be forthe treatment of certain anaerobic and mixed aerobic–anaerobicinfections. It is also used to treat gonorrhea caused byβ-lactamase–producing strains. It is classified as a secondgenerationagent because of its spectrum of activity.
Veterinary Drugs and Treatments
In the United States, there are no cefoxitin products approved for veterinary
species, but it has been used clinically in several species when
an injectable second generation cephalosporin may be indicated.
references
[1]. miller ak, celozzi e, kong y, et al. cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation. antimicrob agents chemother. 1974 jan;5(1):33-7.[2]. jacoby ga. ampc beta-lactamases. clin microbiol rev.2009 jan;22(1):161-82.
Check Digit Verification of cas no
The CAS Registry Mumber 33564-30-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,3,5,6 and 4 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 33564-30:
(7*3)+(6*3)+(5*5)+(4*6)+(3*4)+(2*3)+(1*0)=106
106 % 10 = 6
So 33564-30-6 is a valid CAS Registry Number.
InChI:InChI=1/C16H17N3O7S2.Na/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19;/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22);/q;+1/p-1/t14-,16+;/m1./s1
33564-30-6Relevant articles and documents
Application of Mefoxin (cefoxitin sodium) pharmaceutical preparation in infection prevention in gastrointestinal surgery
-
Paragraph 0133; 0137; 0138; 0142; 0143; 0147, (2019/11/13)
The present invention provides cefoxitin sodium or a composition thereof, a preparation process of the cefoxitin sodium or the composition thereof, a prescribed preparation, a compound preparation, and use. In the cefoxitin sodium or the composition thereof, the mass content of the cefoxitin (C16H17N3O7S2) is 92% or above on an anhydrous basis. The cefoxitin sodium or the composition thereof has good quality stability and a uniform particle size range, can reduce the process difficulty for preparing preparations, can improve clinical curative effects and safety, and can be used for gastrointestinal surgery infection prevention and postoperative infection treatment.
Application of cefoxitin sodium pharmaceutical preparations in preoperative infection prevention for transvaginal hysterectomy, laparoscopic hysterectomy and cesarean section
-
, (2019/11/13)
The present invention provides cefoxitin sodium or a composition thereof, a preparation method of the cefoxitin sodium or the composition thereof, a prescribed preparation, a compound preparation, anduse. In the cefoxitin sodium or the composition thereof, the mass content of the cefoxitin is 93% or above. The cefoxitin sodium or the composition thereof has good quality stability and a low impurity content, facilitating improvement in clinical curative effects and safety. The cefoxitin sodium or the composition thereof has a uniform particle size range, facilitating reduction in the process difficulty for preparing preparations. The cefoxitin sodium or the composition thereof can be used for preoperative infection prevention and postoperative infection treatment for transvaginal hysterectomy, laparoscopic hysterectomy and cesarean section.
Head west spore Ding Na method for the preparation of
-
Paragraph 0042-0044, (2017/03/14)
The invention discloses a preparation method of cefoxitin sodium. The preparation method comprises the following steps: (1) bromizing, for example, the site 7 of a main nucleus of cefalotin by using an NBS (N-bromosuccinimide) reagent to form a bromination compound; performing nucleophilic substitution at the site 5 by using a methoxyl group to generate an intermediate IV; (2) performing acyl group hydrolysis on the site 3 of the intermediate IV to obtain an intermediate V; (3) substituting hydrogen atoms on the hydroxyl group by using chloriosulfonyl isocyanate, and then hydrolyzing to obtain the cefoxitin sodium. The method has the advantages of simple process, high product yield, high purity and high reaction selectivity; no special equipment is used in the production; the preparation method is suitable for industrial production.
